MedTrace Logo

Treatment Outcome of Uveitis in Autoimmune Diseases

NCT03886233 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1

Last updated 2019-03-22

No results posted yet for this study

Summary

reviewing the outcomes of patients with uveitis caused by autoimmune diseases treated at Assiut University Hospital at the Ophthalmology and Rheumatology and Rehabilitation Departments.

Conditions

  • Autoimmune Uveitis

Interventions

DRUG

Corticosteroid Series

immunosuppressives are divided into alkylating agents (cyclophosphamide and chlorambucil), antimetabolites (methotrexate, azathioprine, and Mycophenolate Mofetil), and calcineurin inhibitors (cyclosporine, tacrolimus and sirolimus) Biological anti-inflammatory agents (for exapmle antagonists of tumor necrosis factor alpha like Infliximab and adalimumab).

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Principal Investigators

  • Hasan L Fahmy, Prof. · Assiut University

  • Mohamed G Saleh, lecturer · Assiut University

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-31
Primary Completion
2021-02-28
Completion
2021-02-28
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03886233 on ClinicalTrials.gov